Viatris (NASDAQ:VTRS) said the FDA has declined to approve it and Mapi Pharma's long-acting version of the multiple sclerosis drug glatiramer acetate, or GA, also known as Copaxone. In a statement ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback